A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Inclusion Criteria

• •Safety Lead-In = Male/female ≥ 18 years old
• •Phase 3 and Cohort 3: Male/female ≥ 16 years old (where permitted locally)
• •Histologically or cytologically confirmed Stage IV CRC that contains BRAF V600E mutation
• •Prior systemic treatment in metastatic setting: 0-1 regimens for Safety Lead In; none for Phase 3 and Cohort 3. (Note: Prior adjuvant or neoadjuvant therapy considered metastatic treatment if relapse/metastasis \< 6 month from end of adj/neoadjuvant treatment )
• •Measurable disease (Phase 3 and Cohort 3)/ Measurable or evaluable disease (Safety Lead-in)
• •ECOG PS 0-1
• •Adequate organ function